The Effect of Propranolol and Thioridazine on Positive and Negative Symptoms of Schizophrenia

1985 ◽  
Vol 147 (6) ◽  
pp. 623-630 ◽  
Author(s):  
D. Eccleston ◽  
A. F. Fairbairn ◽  
F. Hassanyeh ◽  
H. A. McClelland ◽  
D. A. Stephens
Keyword(s):  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Blind Study ◽  
Double Blind Study ◽  
Type I ◽  
Type Ii ◽  
Double Blind ◽  
Positive Type ◽  
Negative Type ◽  
Positive And Negative Symptoms

Patients with chronic schizophrenia were treated with either propranolol (640 mg daily) or thioridazine (400 mg daily). In a double-blind study lasting five weeks, propranolol was superior to thioridazine on both psychiatrists' and nurses' ratings. Significant improvements were noted with propranolol in both positive (Type I) and negative (Type II) symptoms.

scholarly journals Erratum: Amisulpride vs Risperidone in Chronic Schizophrenia: Results of a 6-Month, Double-Blind Study

2003 ◽  
Vol 28 (3) ◽  
pp. 611-611 ◽  
Author(s):  
D Sechter ◽  
◽  
J Peuskens ◽  
O Fleurot ◽  
W Rein ◽  
...  
Keyword(s):  
Chronic Schizophrenia ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

A Controlled Trial of Taractan in Chronic Schizophrenia

1963 ◽  
Vol 109 (460) ◽  
pp. 418-421 ◽  
Author(s):  
Eileen P. Scanlan ◽  
Arthur E. May
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

The purpose of this trial was to evaluate the drug Taractan in the treatment of chronic schizophrenia.Taractan (chlorprothixene) is chemically α-2-chloro-9-(w-dimethylamino propylidene)-thioxanthene. It is claimed to have neuroleptic and tranquillizing properties as well as thymoleptic activity. It is also claimed to be relatively free from side-effects. This property facilitated its use in a double-blind study.

Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study

1998 ◽  
Vol 155 (4) ◽  
pp. 499-504 ◽  
Author(s):  
G. Bondolfi ◽  
H. Dufour ◽  
M. Patris ◽  
J. P. May ◽  
U. Billeter ◽  
...  
Keyword(s):  
Chronic Schizophrenia ◽  
Blind Study ◽  
Double Blind Study ◽  
Treatment Resistant ◽  
Double Blind

scholarly journals Atypical antipsychotics and the negative symptoms of schizophrenia

1998 ◽  
Vol 4 (1) ◽  
pp. 53-61 ◽  
Author(s):  
David J. King
Keyword(s):  
Nervous System ◽  
Antipsychotic Medication ◽  
Negative Symptoms ◽  
Atypical Antipsychotics ◽  
Genetic Factors ◽  
Cortical Atrophy ◽  
Positive Symptoms ◽  
Type I ◽  
Type Ii ◽  
Positive And Negative Symptoms

The concept of positive and negative symptoms in schizophrenia can be traced back to Hughlings Jackson (1889) who taught that disease does not create, it sets free, and accordingly positive symptoms could be seen as ‘release’ phenomena resulting from ‘dissolution’ of the highest cerebral centres of the nervous system. Crow (1980) revived the dichotomy and proposed a Type I syndrome, characterised by positive symptoms, and a Type II syndrome, characterised by negative symptoms. He thought the latter was due to cortical atrophy and responded poorly to antipsychotic medication. In their review of the distinction, Walker & Lewine (1988) found a stronger relationship between premorbid dysfunction and negative symptoms than with positive symptoms. They also found there was a stronger influence of genetic factors on negative symptoms than positive symptoms.

Comparison of Efficacy of Timiperone, a New Butyrophenone Derivative, and Clocapramine in Schizophrenia: A Multiclinic Double-Blind Study

1983 ◽  
Vol 11 (5) ◽  
pp. 247-258 ◽  
Author(s):  
T Nakazawa ◽  
K Ohara ◽  
Y Sawa ◽  
T Edakubo ◽  
H Matsui ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Double Blind Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Global Improvement ◽  
Improvement Rate ◽  
Double Blind Method ◽  
Accompanying Symptoms ◽  
Improvement Rating

The clinical efficacy and safety of timiperone, a new butyrophenone derivative, on chronic schizophrenia was compared with clocapramine by the double-blind method using a total of eighty-eight patients, consisting of forty-four patients in each group. In the final global improvement rating, the global improvement rating in each week and the general usefulness rating, there were no statistically significant differences between the two groups. However, in the global improvement rating in each symptom, timiperone was significantly superior to clocapramine in delusion and showed a superior tendency to clocapramine in contact. Timiperone showed a higher improvement rate than clocapramine in hallucination and disturbance of self-conciousness. In the over-all safety rating, there were no significant differences between the two groups, but in accompanying symptoms and side-effects, timiperone showed significantly less tendency than clocapramine in dyskinesia, insomnia, constipation and nausea. From these results, including the analysis by stratification, it was considered that timiperone was a superior or equivalent neuroleptic in comparison with clocapramine against the negative symptoms as well as the positive ones of chronic schizophrenia, and was equally safe or safer than clocapramine.

Sign in / Sign up

Export Citation Format

Share Document